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Volume 50, Number 2 Letters to the Editor 477related to the amount of free cell area between scaffolding compo-
nents. We have a few comments.
From our animal laboratory experience we do agree that
observed velocity alterations seem to be stent type specific.1 Far
more than just free cell area, however, overall stent design and
procedure related properties such as length, sizing, and self-
expandability all influence post-procedural hemodynamic pertur-
bations and velocities, even in the absence of residual stenosis.3
Secondly, concerning the two predominantly used stents,2 the
Wallstent is an example of a Braided Elgiloy Self-Expanding Stent
(BESES) constructed of independent wires. Acculink has a Surface-
Spanning Micro Stent (SSMS) architecture with interconnected
wires, and this, more than free cell area, influences wall apposition
and subsequent alterations in carotid wall mechanics.
Thirdly, stent placement causes a compliance (Cp) mismatch
between the stented part of the artery and its native upstream and
downstream segments. In diseased arteries, the arterial wall con-
tributes to the overall stiffness of the stented site, and this varies
according to the amount of atherosclerosis and calcium load within
the wall. Therefore, final Cp alters to various degrees, which might
explain why DUS velocities are significantly elevated in a percent-
age of patients but not in all.
Fourth, current stents are self-expanding, and their diameters
steadily increase with time (positive arterial remodelling), poten-
tially achieving better expansion of the lumen.4 Serial measure-
ments of stent diameter confirmed continued expansion after
Wallstent deployment, with most marked expansion occurring
during the first three months. Pierce et al aimed to analyze DUS
before and immediately after stenting. However, post-intervention
DUS was obtained in no less than a median five days (range: 1-25
days). This is a serious study limitation, and timing of postoperative
DUS should have been standardized preferentially within 24 hours
and at three months following the procedure. In the meantime,
vascular laboratories should realize that carotid stent placement
itself leads to elevated velocities, which might well be stent type
specific.
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Reply
We appreciate the astute and thoughtful comments regarding
our study. As outlined, it is certainly clear that many factors
contribute to the elastic modulus and compliance of the carotidartery after stenting, which result in changes in flow hemodynam-
ics. Our data highlights the importance of stent design and its
salient role in demonstrating elevated duplex velocities in the
absence of angiographically demonstrable stenosis after carotid
stenting.
We do agree that the optimal timing of postoperative duplex
ultrasound (DUS) after carotid stenting has not been established,
but we doubt this is a real study limitation. Although initially we
obtained duplex scans within 24 hours after stenting, the timing of
the postoperative DUS was later postponed, primarily as a factor of
study design. Many of the patients in our series were enrolled in
post-marketing registries and clinical trials (eg, SAPPHIRE,
CREST, EMPIRE), all of which require post-intervention DUS at
one month. Because most randomized clinical trials assessing
carotid stenting required postoperative DUS at one and six months
and yearly thereafter, such protocols have been widely adopted in
most centers. We believe that DUS at one month should serve as a
baseline study and that changes in blood flow velocities related to
stent design are validated at this time period. Obtaining DUS at one
and 90 days, as suggested, may be unnecessary, cost-ineffective, and
clinically impractical. Obviously, long-term changes in blood flow
velocities related to stent design and incidence of in-stent restenosis
need to be further investigated. In this regard, we are currently
conducting studies to quantify to what extent stent design differences
in carotid velocities may influence DUS criteria for precisely defining
restenosis after carotid artery stenting.
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Regarding “A randomized trial of cryo stripping
versus conventional stripping of the great
saphenous vein”
It was with great interest that we read the article by Klem et
al,1 describing a trial comparing two methods of stripping of the
great saphenous vein (GSV). They are to be complimented on
having presented a clearly honest and large prospective series on
cryo stripping. However, some comments have to be made.
The first comment is on the primary outcome, residual GSV at
6 months. Although it seems likely that residual GSV will influence
the outcome at long-term, little is known about this phenomenon.
We do know that residual veins after endovascular treatment do
not correlate well with clinically recurrent disease. It is a pity,
therefore, that authors did not mention clinical recurrent disease at
follow-up; this should have given us at least an impression, espe-
cially since both techniques performed the same in the quality of
life scores.
Second, I would like to comment on the technique used. Most
surgeons that use the cryo device freeze much shorter than 10
seconds: 3 to 5 seconds suffice to adhere the vein to the probe, and
in such manner, a much smaller part of the adjacent tissue will
freeze together with the vein. Generally thereafter, the vein may be
extracted after invagination, causing less tissue damage, and en-
abling a second or third passage of the probe in case the vein
ruptures during extraction. Invagination is generally not possible
when the cryo probe is used in the “classic” manner, with a large
block of frozen tissue at the tip. The less subtle stripping, and the
necessity of a cosmetically unwanted and time consuming distal
incision in conventional stripping are the main reasons for using
the cryo probe.
Third, I would like to emphasize the fact that significantly
more of the patients lost for follow-up were in the conventional
